2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-123666
    Bay-02752 78991-74-9 98%
    Bay-02752 (Bay o 2752) is a lipid-lowering agent. Bay-02752 inhibits acyl-CoA activity in liver microsomes (IC50 = 0.95 μg/mL). Bay-02752 inhibits intestinal cholesterol absorption in rats. Bay-02752 inhibits gallstone formation in hamsters.
    Bay-02752
  • HY-123679
    FR168888 168620-46-0 98%
    FR168888 is an inhibitor of Na+/H+ exchange with a Ki value of 6.4 nM.
    FR168888
  • HY-123705
    Ronifibrate 42597-57-9 98%
    Ronifibrate is a fibrate and a PPARα activator. Ronifibrate can be studied in research on hyperlipidemia.
    Ronifibrate
  • HY-123721
    Tiracizine hydrochloride 78816-67-8 98%
    Tiracizine hydrochloride (AWD-19-166) is a Class I antiarrhythmic drug with activity that reduces myocardial contractile function. Tiracizine hydrochloride was studied in patients with ischemic heart disease, showing its effects on the myocardium. Tiracizine hydrochloride reduces myocardial contractility and may have potential use in the management of heart disease.
    Tiracizine hydrochloride
  • HY-123793
    MK-1832 935868-50-1 98%
    MK-1832 (Compound 32) is a selective Kv1.5 inhibitor (IC50 = 86 nM). MK-1832 is a P-glycoprotein substrate. MK-1832 can be used in atrial fibrillation research.
    MK-1832
  • HY-123799
    SB-699393 502638-39-3 98%
    B-699393 (Compound 17) is a BRAF inhibitor (Kd = 7.2 nM) that can cross the blood-brain barrier. SB-699393 can be used for research on stroke.
    SB-699393
  • HY-123803
    PF-06807656 2213468-04-1 98%
    PF-06807656 is a selective renal outer medullary potassium channel (ROMK or Kir1.1) inhibitor. PF-06807656 has an IC50 of 61 nM against hROMK in patch-clamp assays. PF-06807656 exhibits high selectivity for inhibiting rat ROMK and is insensitive to N171D pore mutations. PF-06807656 may be used in cardiovascular disease research.
    PF-06807656
  • HY-123864
    SC-68448 188804-07-1 98%
    SC-68448 (S 448) is a selective αvβ3 antagonist (IC50 = 1 nM). SC-68448 inhibits αvβ3-mediated endothelial cell proliferation. SC-68448 reduces the total level of αvβ6 in NHBE cells. SC-68448 inhibits angiogenesis in a rat corneal neoplasia model. SC-68448 inhibits tumor growth and completely prevents the development of hypercalcemia in a rat Ledich cell tumor model. SC-68448 can be used in research on cardiovascular and cerebrovascular diseases such as hypercalcemia and cancers such as testicular interstitial cell tumors.
    SC-68448
  • HY-123958
    SB772077B 785774-34-7 98%
    SB772077B is a ROCK inhibitor. SB772077B has an anti-inflammatory activity and enhances aqueous outflow facility (OF) by inactivating RhoA/ROCK signal pathway. SB772077B significantly reduces the mRNA level of β-catenin and protein level of fibrotic markers, such as vinculin, fibronectin, collagen 1 A and vimentin. SB772077B also has vasodialatory activity and decreases pulmonary and systemic blood pressure. SB772077B can be used for glaucoma research and pulmonary hypertensive disorder research.
    SB772077B
  • HY-124044
    ML 086 1177148-36-5 98%
    ML 086 is a highly selective PHOSPHO1 phosphatase inhibitor (IC50=0.14 μM). ML 086 is promising for research of hereditary vascular calcification disorders (e.g., generalized arterial calcification of infancy) and spinal ligament ossification.
    ML 086
  • HY-124074
    S-3448 254877-04-8 98%
    S-3448 is a derivative of Ataciguat (HY-17500). S-3448 is a Soluble guanylate cyclase (sGC) agonist. S-3448 activates both the haem-containing and the haem-deficient form of sGC without depending on NO and heme. S-3448 can be used for cardiovascular diseases such as arterial hypertension and pulmonary hypertension research.
    S-3448
  • HY-124104
    Aldicarb sulfoxide 1646-87-3 98.41%
    Aldicarb sulfoxide is a metabolite of Aldicarb. Aldicarb sulfoxide affects the glutathione-linked enzymes in CHO-K1 cells. Aldicarb sulfoxide inhibits cholinesterase (ChE) and carboxylesterase (CaE) with IC50 of 10 μM for both in zebrafish.
    Aldicarb sulfoxide
  • HY-124109
    TRC051384 hydrochloride 1333327-56-2 98%
    TRC051384 hydrochloride is a potent inducer of heat shock protein 70 (HSP70). TRC051384 hydrochloride exhibits protective effects against neuronal trauma via inhibition of necroptosis. TRC051384 hydrochloride can be used for the research of ischemic stroke.
    TRC051384 hydrochloride
  • HY-124133
    JNJ-42905343 1238689-36-5 98%
    JNJ-42905343 is an orally active and highly selective prolyl hydroxylase (PHD1/2/3) inhibitor with pKI values of 8.07, 7.48 and 7.27 for PHD1, PHD2 and PHD3, respectively. JNJ-42905343 is promising for research of functional iron deficiency (FID) and anemia of chronic disease (ACD).
    JNJ-42905343
  • HY-124150
    BM567 284464-77-3 98%
    BM567 is a sulfonylurea compound (compound 1), which exhibits antithrombogenic efficacy as thromboxane A2 receptor (TXR) antagonists and thromboxane A2 synthase (TXS) inhibitors, with IC50s of 1.1 and 12 nM, respectively.
    BM567
  • HY-124153
    GNE-431 1433820-83-7 98%
    GNE-431 is a potent, selective and noncovalent “pan-BTK” inhibitor against C481R, T474I and T474Ms mutants. GNE-431 shows potency against wild-type BTK (IC50= 3.2 nM) and potency against C481S mutant (IC50= 2.5 nM). GNE-431 is proming for rasearch of haematological disorders and autoimmune diseases.
    GNE-431
  • HY-124176
    L-6355 85642-08-6 98%
    L-6355 is an Amiodarone (HY-14187) related compound, which inhibits Ca2+/calmodulin activated cyclic nucleotide phosphodiesterase with an IC50 value of 0.65 μM. L-6355 is promising for research of antiarrhythmic and antianginal agent.
    L-6355
  • HY-124234
    TA-0201 169679-53-2 98%
    TA-0201 is a novel orally active, competitive, non-peptide endothelin receptor antagonist. TA-0201 antagonizes the specific binding of [125I]ET-1 to cloned human receptors of ETA and ETB with Ki values of 15 pM and 41 nM, respectively. TA-0201 inhibits the pressor response to the exogenous big ET-1.
    TA-0201
  • HY-124363
    5-cis Carbaprostacyclin 69609-77-4 98%
    5-cis Carbaprostacyclin is a stable analog of PGI2 based on Carbaprostacyclin (HY-112322). Carbacyclin is a PGI2 receptor agonist and vasodilator that activates PPARδ. 5-cis Carbaprostacyclin induces relaxation of pulmonary vascular tone.
    5-cis Carbaprostacyclin
  • HY-124371
    Amentoflavone hexaacetate 17482-37-0 98%
    Amentoflavone hexaacetate is a 3,5-cyclic nucleotide phosphodiesterase inhibitor with antiplatelet aggregation activity. Amentoflavone hexaacetate can inhibit the aggregation of eluted human platelets induced by ADP or collagen. Amentoflavone hexaacetate can also inhibit the cAMP phosphodiesterase activity in human platelets. Amentoflavone hexaacetate can significantly increase the cAMP level of platelets in the presence of prostaglandin E1. Amentoflavone hexaacetate has anti-angiogenic and anti-metastatic effects.
    Amentoflavone hexaacetate
Cat. No. Product Name / Synonyms Application Reactivity